Anti-proliferative effects of MEK1/2 inhibitors have been reported in many cell types, including ovarian cancer cells, and cause G1/0-phase cell cycle arrest due to loss of ERK1/2 activation [38,61,66,67]. Here, MAP2K1 is linked to ovarian carcinoma.